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The effect of the two antibiotics ceftazidime and meropenem on a collection of 46 Burkholderia pseudomallei
isolates representing clinical and environmental sources across northern Australia was investigated by using
a series of in vitro test methods. The susceptibility testing methods used included Kirby-Bauer disk diffusion,
Etest MIC, broth microdilution MIC, and a modification of the microdilution method in which Acanthamoeba
cells were added to simulate the effect of a professional phagocytic cell on test outcome. In a semiquantitative
validation coculture series, the majority of bacteria were intracellular up to a multiplicity of infection of 10
bacteria to one ameba. The optical density and bacterial count (log10 CFU/ml) correlated across the range
tested (r2  0.77; P < 0.0001). Susceptibility test results were compared against clinical outcomes. The MICs
of ceftazidime were consistently higher than those of meropenem by all three methods. The MICs of both agents
were significantly higher when Acanthamoeba trophozoites were added to the broth microdilution method.
Conventional and intracellular MIC results were consistent for clinical isolates from the Western Australian
outbreak cluster despite the wide variety of clinical outcomes. Further development of the intracellular MIC
method is expected to help assess the efficacy of antimicrobial agents on this bacterial species in an intracel-
lular setting.
Burkholderia pseudomallei, the bacterial species responsible
for the potentially fatal infection known as melioidosis, is a
facultative intracellular pathogen. The ability of B. pseudoma-
llei to survive in macrophages has been known for some time
(10) and is used to explain unusual aspects of melioidosis
including late onset and recurrent disease. Treatment of the
acute, septicemic form of melioidosis often relies on ceftazi-
dime. In a study with a septicemic relapse rate of around 23%,
relapse was more common in the patient group not treated
with ceftazidime (1). The combined mortality of septicemic
and nonsepticemic melioidosis in Australia has been put at
21% (2). There has been growing interest in the use of car-
bapenems as an alternative antibiotic option for acute B.
pseudomallei infection (12, 13). At present, clinical trial data
do not conclusively demonstrate an improved outcome when
carbapenems are compared with ceftazidime (12), despite the
theoretical benefit expected from improved intracellular pen-
etration. In a recent case study, a previously published amebic
cellular model of B. pseudomallei infection was used to dem-
onstrate the superior intracellular activity of meropenem over
ceftazidime and sulfamethoxazole (7). Although it was found
that improved in vitro activity corresponded to the clinical
improvement in a single persistent septicemic case, this out-
come had alternative explanations based on other aspects of
patient care. In the present study we used an amebic intracel-
lular susceptibility method to compare the activity of a carbap-
enem and ceftazidime on a range of B. pseudomallei isolates
from our culture collection.
MATERIALS AND METHODS
Bacterial strains. Forty-six isolates of B. pseudomallei were used in this study,
comprising the three reference strains NCTC 10276, DM 98 (persistently mucoid
colony phenotype), and NCTC 13177 (Western Australian outbreak strain [5]);
environmental isolates (13); and a geographically representative collection of
Australian clinical isolates (36). These strains had already been genotyped by
automated EcoRI ribotyping and DNA macrorestriction, as previously described
(8). Apart from three groups of genotypically clustered isolates (Table 1), in-
cluding the Western Australian outbreak group, all isolates belonged to distinct
strains. B. pseudomallei isolates were stored in replicate 1-ml containers of 20%
glycerol-brain heart infusion broth at 70°C and recovered by subculture onto
5% horse blood agar (Excel Laboratory Products, Bentley, Western Australia,
Australia) and incubation in air for 18 h at 37°C. Three non-B. pseudomallei
reference strains were used for quality control purposes in the disk diffusion and
broth microdilution tests. These were Staphylococcus aureus ATCC 25923,
Pseudomonas aeruginosa ATCC 27853, and Escherichia coli ATCC 25922.
Amebas. The strain used in this study was Acanthamoeba astronyxis CCC 111,
which was maintained in peptone glucose yeast extract broth at 20°C. Cells were
harvested from tissue culture flasks, centrifuged, and resuspended in sterile
0.89% NaCl solution (Excel).
Antibiotic reagents. Fresh antibiotic-containing disks and Etest strips were
used for susceptibility testing. In order to replicate in-use conditions in the
intracellular susceptibility test, commercially available, in-date meropenem and
ceftazidime intravenous formulations were used to make up fresh solutions
immediately prior to each experiment.
Microtiter coculture of bacteria and amebas. Bacteria-ameba coculture was
conducted under semiquantitative conditions in order to determine the optimal
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TABLE 1. Disk diffusion and Etest results
Isolate
Inhibition zone diam (mm) Etest MIC (g/ml) Related
isolatesaCeftazidime Meropenem Ceftazidime Meropenem
Reference S. aureus ATCC 25923 20 (16) 35 (16) 0.032
Reference E. coli ATCC 25922 27 (16) 33 (16) 0.008
Reference P. aeruginosa ATCC 27853 27 (16) 33 (16) 0.19
Reference B. pseudomallei strains
NCTC 10276 25 27 2 1
DM 98 (mucoid) 27 16 4 4
NCTC 13177 29 27 2 1 A
Western Australia clinical B.
pseudomallei isolates
BCC 1 28 25 2 1.5 B
BCC 2 27 25 2 1.5 A
BCC 3 28 25 2 1 A
BCC 4 28 25 2 1 A
BCC 8 29 27 3 0.75 A
BCC 16 27 26 2 1 B
BCC 33 28 26 2 1 A
BCC 36 29 25 2 1 A
BCC 71 27 24 2 1.5
BCC 74 24 25 2 0.75
BCC 105 25 22 3 1.5 C
BCC 107 27 25 3 1.5
BCC 109 27 26 3 1.5 C
BCC 110 25 23 3 1.5 C
BCC 122 25 25 4 1
Queensland clinical B. pseudomallei
isolates
BCC 75 29 25 3 1
BCC 76 28 27 3 1.5
BCC 77 25 26 3 1
BCC 78 29 27 3 1.5
BCC 79 28 25 2 1
BCC 80 28 27 3 1.5
BCC 81 27 26 3 1
BCC 83 27 26 3 1.5
BCC 85 28 27 3 1.5
BCC 86 29 26 3 1.5
BCC 87 25 26 4 1
Northern Territory clinical B.
pseudomallei isolates
BCC 18 27 27 3 1.5
BCC 49 26 27 3 1
BCC 50 28 26 2 1.5
BCC 51 27 24 3 1.5
BCC 52 26 24 3 1.5
BCC 53 26 26 3 1
BCC 69 30 31 2 0.5
BCC 72 25 24 3 1.5
Australian environmental B.
pseudomallei isolates
BCC 21 28 23 2 1.5 A
BCC 22 0 24 256 0.38
BCC 23 29 26 2 0.75
BCC 24 30 28 0.75 0.5
BCC 26 26 25 3 1.5
BCC 27 30 25 1.5 1
BCC 28 25 25 3 1.5
BCC 29 26 25 3 0.75
BCC 30 25 25 2 1
BCC 31 28 25 2 1
BCC 44 28 26 2 1.5 A
BCC 45 29 25 2 1.5 A
BCC 46 29 25 2 1 A
a Related isolates are groups of epidemiologically related bacteria that cluster by genetic typing.
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bacterial inoculum to ensure the internalization of bacteria by amebas. A 96-well
flat-bottomed microtiter plate was used (Nunc Nalge), with rows A to D for the
NCTC 10276 series and rows E to H for the NCTC 13177 series. Each set of four
rows was divided into four blocks of wells, each in a pattern of three by four wells.
The first block was reserved for saline and tryptic soy broth (TSB; Excel) sterility
controls. The second block was loaded with 50 l of B. pseudomallei cell sus-
pension in TSB, going from undiluted mid-lag phase culture in row A, stepwise
to 103 mid-lag phase culture in row D. There were two replicates in columns 5
and 6, making a total of three wells at each dilution. A 50-l aliquot of sterile
0.85% NaCl solution was added to each of these wells to make a total of 100 l
per well. In the third block, the wells were filled with a 50-l aliquot of Acan-
thamoeba cell suspension and made up to 100 l by adding 50 l of sterile TSB.
All wells in the third block contained the same concentration of Acanthamoeba
cells. The fourth and final block of wells contained 50 l of Acanthamoeba cell
suspension at constant concentration and 50 l of B. pseudomallei cell suspension
in TSB, following the same dispensing pattern as block B, from undiluted lag
phase in row A to 103 mid-lag phase culture in row D. The optical density of
each well was measured by an automated plate reader at 450-nm absorbance
immediately after completion of the well inoculation phase and again after a 24-h
incubation at 20°C in air. The change in optical density for each well was
determined by subtracting the baseline reading (at time zero) from the 24-h
reading. A 10-l aliquot was taken from below the surface of each well by using
a 10-l displacement pipette and a sterile, aerosol-free tip. This aliquot was
dispensed into 0.85% NaCl solution to create a series of dilutions according to
the measured optical density of each well. A 50-l aliquot of the final dilution
chosen for each well was spread onto plate count agar (Excel) by using a spiral
plater and incubated for 24 h in air at 37°C. Plate counts were then determined
and converted to log10 CFU per ml. A 10-l aliquot from the remaining contents
of each well from the first row of each preparation was dispensed onto a fresh
glass microscope slide, covered with a glass coverslip, and sealed with clear nail
polish. The sealed coverslip preparation was examined on a Bio-Rad MRC
1000/1024 UV laser scanning confocal microscope equipped with a Nikon 60
NA 1.2 water immersion objective. Images were captured at the same magnifi-
cation by using the monochrome transmission detector on the microscope and
focused in a plane between the coverslip and the slide surfaces. Repeat experi-
ments were conducted over a longer (48-h) incubation period and with incuba-
tion at 37°C in air.
Conventional susceptibility tests. Disk diffusion determinations were per-
formed according to a previously described Kirby-Bauer method (11), though
disk diffusion has not been formally validated for susceptibility testing of B.
pseudomallei by the NCCLS, and an interpretive standard has not been estab-
lished. Meropenem and ceftazidime were tested. Zones were measured at three
evenly spaced diameters with calipers, and the mean diameter was calculated.
The interpretation of results was based on the NCCLS zone diameters used for
non-Enterobacteriaceae. The MICs of meropenem and ceftazidime were deter-
mined by Etest as previously described (4).
Microdilution MIC. A broth microdilution method was used for meropenem
and ceftazidime MIC determinations. An inoculum of 106 CFU of washed B.
pseudomallei per ml was used, and the test was conducted in Mueller-Hinton
broth (MHB; Excel). The interpretation of results was based on the NCCLS MIC
breakpoints for non-Enterobacteriaceae. The Etest-determined MIC was used to
establish the midpoint of the twofold antibiotic dilution series for the MIC
obtained by the broth microdilution method. A parallel series of antibiotic
dilutions was conducted in MHB containing A. astronyxis at a multiplicity of
infection (MOI) of 10 bacteria to 1 ameba. Plates were covered and incubated at
37°C in air for 18 h. The MIC was then read visually. Wells containing amebas
but no bacteria were included as a negative growth control. Aliquots (10-l) were
examined at a magnification of400 under phase contrast to confirm the phago-
cytosis of bacilli by amebas.
Statistics and data interpretation. The MIC endpoints were determined by a
standard method. Results were analyzed and compared by using statistical soft-
ware (Prism version 2.01; GraphPad, San Diego, Calif.). Where the endpoints for
MICs obtained by microdilution were unclear, the lowest dilution at which any
inhibition occurred was taken to indicate the MIC.
RESULTS
Validation of microtiter coculture method. Confocal micro-
scope views of coculture preparations confirmed that the prin-
cipal contributor to the increased optical density in microtiter
coculture wells was bacterial growth (Fig. 1). A comparison of
cocultures at four different MOIs demonstrated that the ma-
FIG. 1. Contents of microtiter coculture wells. Differential interference microscope images of microtiter wells containing A. astronyxis and B.
pseudomallei NCTC 10276 in coculture after 24 h of incubation at 20°C. The most visibly opaque wells contained bacteria and no amebas,
corresponding to the highest MOI (100) (frame 1). At progressively lower MOIs (frames 2 to 4), there were fewer bacteria and more surviving
amebas, and intracellular bacteria were evident. Scale bar, 10 m.
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jority of bacteria were intracellular until the MOI reached 10:1.
The series of cocultures with B. pseudomallei NCTC 10276
amebas demonstrated a progressive increase in optical density
with increasing bacterial inoculum in the bacteria-only and
coculture wells (Fig. 2). The ameba-only control wells showed
no such change. There was a decrease in optical density in the
coculture wells compared with the corresponding bacteria-only
wells, consistent with the phagocytosis of bacteria. The optical
density increase over 24 h correlated with the final bacterial
count attained in each microtiter well (log10 CFU/ml) (r
2 
0.77, P  0.0001). Longer incubation (48 h) and higher incu-
bation temperature both led to early pellicle growth, which
interfered with accurate optical density measurement.
Disk diffusion. According to disk diffusion testing, only one
isolate was resistant to meropenem, and another one was re-
sistant to ceftazidime. Both of these isolates were sensitive to
the other antimicrobial agent. These isolates had susceptibility
results that were distinct from those of the other isolates tested
(Table 1). The meropenem-resistant isolate had a smaller in-
hibition zone (15.7 mm) than sensitive isolates (20 to 25 mm)
and was a persistently mucoid isolate whose zone diameter was
difficult to read. The ceftazidime-resistant isolate had no cefta-
zidime inhibition zone at all, compared to 24 to 29 mm for
ceftazidime-sensitive isolates.
Etest. Etest results gave meropenem MICs of 0.38 to 4.0 g
per ml, the highest reading being the most resistant isolate by
disk diffusion (Table 1). The most meropenem-sensitive isolate
was the ceftazidime-resistant isolate, which was also fully cefta-
zidime resistant by the Etest. The other ceftazidime Etest
results were 0.75 to 4.0 g/ml. The isolate with the highest
measurable ceftazidime Etest result also produced the highest
Etest meropenem MIC.
Broth microdilution. MIC results are summarized in Table
2. Ceftazidime Etest MIC results correlated with conventional
broth microdilution MIC results but not with the intracellular
ceftazidime MICs (Table 3). There was no significant correla-
tion between Etest meropenem MICs and MICs determined
by the other two methods. Meropenem Etest results were
tightly grouped, reducing the prospects of validating a wide test
range. For three isolates, the meropenem microdilution MICs
were 16 g/ml with no clear endpoint but with Etest results
of 1.0 to 1.5 g/ml.
The addition of amebas to the test wells in the broth mi-
crodilution series led to significant increases in the MICs of
both antibiotics. Microdilution MICs of ceftazidime were sig-
nificantly higher than those of meropenem with and without
amebas in the test wells (Fig. 3). These results represented the
results of total bacterial growth following intracellular bacte-
rial survival, which at the starting MOI was largely intracellular
(Fig. 1). The conventional broth microdilution MICs of both
antibiotics correlated with the intracellular MICs (Fig. 4 and
Table 3). Etest MIC results correlated only with conventional
ceftazidime microdilution MICs and did not correlate with
either the meropenem microdilution MICs or the meropenem
and ceftazidime intracellular MICs.
Clinical outcomes. The patients from whom B. pseudomallei
was isolated represented three jurisdictions in northern Aus-
tralia. Six patients died, all in the early stages of acute disease.
The duration of the hospital stays of the survivors was between
7 days and 8 weeks. The conventional meropenem MIC was
consistently within two dilutions of the intracellular MIC for all
the isolates representing the Western Australian melioidosis
cluster, whether patients died (three patients), recovered (two
patients), or had delayed onset infection (two patients). There
was no significant positive correlation between the duration of
hospital stay and MIC. Only two surviving patients stayed in
FIG. 2. Comparison of optical density change over 24 h and final
bacterial colony count in microtiter coculture of B. pseudomallei
NCTC 10276 with A. astronyxis. x axis, optical density at 450 nm at 24 h
of incubation; y axis, log10 CFU of B. pseudomallei per ml at 24 h.
Linear regression and 95% confidence limits are indicated (r2  0.77,
P  0.0001). OD, optical density.
TABLE 2. Summary of MIC test results by Etest, conventional broth microdilution, and intracellular microdilution for B. pseudomallei
susceptibility to ceftazidime and meropenema
Antibiotic Method
MIC (g/ml)
MIC50 MIC90 Range Median
Meropenem Etest 1.0 1.5 1.0–4.0 3.0
Meropenem Conventional 3.0 4.0 2.0–6.0 3.0
Meropenem Intracellular 8.0 16.0 1.5–32 6.0
Ceftazidime Etest 3.0 4.0 1.5–256 4.0
Ceftazidime Conventional 4.0 32.0 1.5–32 4.0
Ceftazidime Intracellular 16.0 32.0 2.0–32 12.0
a Broth microdilution MICs for control strains were as follows: S. aureus ATCC 25923, 0.25 g/ml; E. coli ATCC 25922, 0.031 g/ml; and P. aeruginosa ATCC
27853, 1.0 g/ml.
b MIC50, the MIC at which 50% of the strains are inhibited; MIC90, the MIC at which 90% of the strains are inhibited.
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hospital for more than 4 weeks, and in the case of one of these
patients, high-level cotrimoxazole resistance was thought to
have been a contributory factor. The meropenem-resistant
strain came from a septicemic patient treated successfully with
ceftazidime. The ceftazidime-resistant strain was a soil isolate
that has not yet been detected in clinical specimens.
DISCUSSION
When ceftazidime was shown to halve the mortality from
severe melioidosis in a randomized clinical trial, it became the
treatment of choice for the intensive ´ form of the infection
(15). Shortly after these trial results were published, carbap-
enems were shown to have good in vitro activity against B.
pseudomallei in a study of acquired antibiotic resistance (3),
but it took longer to establish the efficacy of the carbapenem
group as a whole against ceftazidime-resistant strains and even
longer to test the carbapenems in a clinical trial setting (12,
13). Acquired antibiotic resistance to ceftazidime can be de-
tected by conventional in vitro susceptibility test methods in
only a small proportion of strains (3, 9). Of the various sus-
ceptibility test methods used to explore the relationship be-
tween antibacterial activity and clinical outcome, none has
proved ideal, particularly in resolving the issue of how best to
prevent late relapse. A promising start has been made on this
problem by using a mouse melioidosis model, in which a com-
bination of ceftazidime and cotrimoxazole was found to be
more effective than ceftazidime monotherapy (14).
A previous report of an intracellular susceptibility test
method led us to seek a method to screen larger numbers of B.
pseudomallei strains for intracellular antibacterial susceptibility
(7). Results from initial in vitro coculture studies indicated that
the opacification of the growth media was due to a combina-
tion of intracellular and extracellular growth resulting from
bacterium-ameba interactions (6). The validation steps we
completed in the present study indicate that while the method
aims to assess intracellular antimicrobial efficacy, bacterial
growth detected by direct visual inspection is extracellular. The
microtiter method must, therefore, be regarded as indirect and
semiquantitative. The tendency of B. pseudomallei to form a
pellicle when grown for longer periods or at higher incubation
temperatures prevented the use of MHB at 37°C for the semi-
quantitative validation experiment, though this combination
was necessary to allow some degree of extrapolation to con-
ventional broth microdilution MIC methods. Although pellicle
formation might have interfered with light scattering during
optical density measurement, this effect can only occur when
an excess of extracellular bacilli is present. In our experience
this was an easily visible indication of sub-MIC antibiotic con-
centrations. While possibly a better indicator of intracellular
antimicrobial effect, this method may not be suited to incuba-
tion periods longer than 24 h or higher MOIs or incubation
temperatures.
Our results confirm that the majority of Australian B.
pseudomallei isolates tested are sensitive to both meropenem
and ceftazidime in vitro but with generally reduced suscepti-
bility in a cellular environment. Interestingly, the single-agent-
resistant strains detected by disk diffusion testing were mucoid
variants with a colony phenotype similar in appearance to
mucoid P. aeruginosa. It is possible that this phenotype may
FIG. 3. Microdilution MICs of ceftazidime and meropenem without amebas (broth microdilution MIC [bm MIC]) and with amebas (intra-
cellular MIC [iMIC]) in the test wells. Results for both drugs were significantly different by a paired t test (for ceftazidime: P  0.0001, pairing
P  0.0002; for meropenem: P  0.0001, pairing P  0.0004).
TABLE 3. Correlation between Etest, conventional broth microdilution, and intracellular microdilution MIC determinations of B.
pseudomallei susceptibility to ceftazidime and meropenema
Antibiotic Method 1 Method 2 Correlation P r
Ceftazidime Etest Conventional Yes 0.0042 0.42
Ceftazidime Etest Intracellular No
Ceftazidime Conventional Intracellular Yes 0.0015 0.46
Meropenem Etest Conventional No
Meropenem Etest Intracellular No
Meropenem Conventional Intracellular Yes 0.0028 0.43
a Spearman coefficient for non-Gaussian data.
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also cause difficulties for the determination of suitable inter-
pretive standards. The Etest results corroborate the disk dif-
fusion test results and also provide an estimate of the MIC.
MIC testing of agents against B. pseudomallei raises issues of
accuracy, significance, and relevance. Broth microdilution, par-
ticularly when applied to ceftazidime MIC determination, was
prone to difficulty in establishing a clear endpoint. The Etest,
on the other hand, gave a clear endpoint except in the case of
the ceftazidime-resistant isolate for which the MIC was im-
measurably high. In other cases the Etest put the MIC lower.
Ceftazidime MICs obtained by the Etest correlated with MICs
obtained by the microdilution method. The Etest meropenem
MICs were so tightly grouped between 0.5 and 1.5 g/ml (ex-
cepting the resistant isolate) that correlation with microdilu-
tion MIC results was not expected.
The addition of a cellular component to the broth microdi-
lution MIC method raised the MIC of both antibiotics for the
majority of isolates tested. The differential was greatest for
ceftazidime and may have been underestimated by the conven-
tion of using the lowest inhibitory value for statistical determi-
nations. Nevertheless, the majority of meropenem MICs ob-
tained by both methods were below 10 g/ml, while the
majority of ceftazidime MIC results were below 10 g/ml only
when amebas were absent. This suggests that the action of the
carbapenem antibiotic is affected less than that of the cepha-
losporin by the addition of amebas. If these results are genu-
inely representative of bacterium-eukaryotic cell interactions
in a clinical setting, they suggest that the majority of isolates we
tested are capable of functional resistance to ceftazidime and,
to a lesser extent, to meropenem in a cellular environment. As
intra-amebic antibiotic levels were not measured and antibiot-
ic-mediated effects on the amebas were not sought, caution
should be exercised in attributing the results of this preliminary
study solely to differences in intracellular antibiotic action.
The range of clinical outcomes in the patients whose isolates
we tested could not have been predicted by the disk diffusion,
Etest, or broth microdilution methods of determining MICs.
Though both the conventional and intracellular MIC methods
suggest that meropenem might be more effective than ceftazi-
dime in vitro, this was not clearly reflected by the clinical
outcomes. The one group of seven patients infected by a single
strain of B. pseudomallei from a probable point source illus-
trates the importance of the host response in determining
clinical outcome (of five who had early onset infection, two
died quickly, and neither of the two who had late onset infec-
tion died). The remaining patients represent the two centers
with the most melioidosis patients and cover a range of anti-
biotic regimes. No subgroup was large enough to allow analysis
of the possible predictive value of the intracellular MIC. The
complexities of intensive (acute) and convalescent or eradica-
tion (maintenance) regimens need to be investigated system-
atically in a series of in vitro and clinical studies. In particular,
the intracellular MIC needs investigation as a predictor of
clinical outcomes in a much larger patient group, especially in
studies of potentially synergistic combinations of meropenem
or ceftazidime used with supplementary eradication agents.
In conclusion, this comparative study of the susceptibility of
a B. pseudomallei culture collection to meropenem and cefta-
zidime found a reduced susceptibility to both agents when an
intracellular susceptibility test method was used. Comparison
of test results with clinical outcomes points to host factors as
the predominant determinant of outcome. This study provides
preliminary data indicating a degree of internal consistency
between the differing methods chosen and some potentially
interesting differences. Though it is too early to say how intra-
cellular susceptibility testing of B. pseudomallei might be ap-
plied in clinical practice, further refinement of an intracellular
method may produce valuable insights into the effect of im-
portant therapeutic agents on this species in a cellular milieu.
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